Pay in 4 interest-free payments of $5.88 Learn more
Ships within 48 hours Β· Estimated delivery Aug 14 - Aug 19
In the SURMOUNT-1 trial, tirzepatide produced average weight loss of: 5 mg dose: 15.0% body weight reduction 10 mg dose: 19.5% body weight reduction 15 mg dose: 20.9% body weight reduction These results came from 72 weeks of carefully titrated, medically supervised treatment
Were now seeing bad actors use the compounding label to mass-produce and market GLP-1 drugs that havent undergone the safety testing required of FDA-approved products
Understanding proper peptide storage and post-reconstitution storage becomes especially important during extended protocols where supply management is a practical concern
Retatrutide ("Reta") Is Trending on Social Media
2024 DOI: 10.1038/s41591-024-03018-2 PMID: 38858523 Read on PubMed Cell Metabolism LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept Coskun T, Urva S, Roell WC, et al
It remains unlicensed, unavailable outside authorised clinical trials, and prohibited under WADA and UKAD anti-doping rules
US$ 20.12
US$ 28.68
US$ 21.44
